← Literature

Oral Treatment with MK-677, a Novel Growth Hormone Secretagogue, in Obese Patients: A Double-Blind, Placebo-Controlled Study

rct • 2006 • ID: 16511387

Moderate Confidence RCT

Primary source: [Open]

Linked compounds: ibutamoren

Outcomes summary

Double-blind, placebo-controlled clinical study evaluating MK-677 (ibutamoren) in obese patients; treatment demonstrated significant increases in serum IGF-1 concentrations compared to placebo; the study confirmed the compound's bioavailability and ability to chronically activate the growth hormone receptor pathway via oral administration in human subjects.

Limitations

Relatively small sample size and limited treatment duration; long-term safety and efficacy data are lacking; potential impacts on glucose metabolism were not fully characterized over extended treatment; study focused on pharmacodynamic endpoints rather than clinical outcomes.

Notes

Primary source: PMID 16511387 (see PubMed link on this page).